These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 25941160

  • 21. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
    Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ.
    Diabetes Care; 2015 Feb; 38(2):e15-7. PubMed ID: 25614693
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
    Durán-Garcia S, Lee J, Yki-Järvinen H, Rosenstock J, Hehnke U, Thiemann S, Patel S, Woerle HJ.
    Diabet Med; 2016 Jul; 33(7):926-33. PubMed ID: 26605991
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C.
    Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
    Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Ouwens DM, Hartmann B, Holst JJ, Danser AHJ, Joles JA, van Raalte DH.
    Diabetes Obes Metab; 2022 Jan; 24(1):115-124. PubMed ID: 34580975
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.
    Nauck M, Araki A, Hehnke U, Plat A, Clark D, Khunti K.
    Int J Clin Pract; 2018 Oct; 72(10):e13240. PubMed ID: 30216648
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
    Mu Y, Pan C, Fan B, Hehnke U, Zhang X, Zhang X, Wang X, Liu J, Zhang Y, Du J, Ma J, Gong Y.
    Diabetes Res Clin Pract; 2017 Feb; 124():48-56. PubMed ID: 28088030
    [Abstract] [Full Text] [Related]

  • 34. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
    Groop PH, Del Prato S, Taskinen MR, Owens DR, Gong Y, Crowe S, Patel S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2014 Jun; 16(6):560-8. PubMed ID: 24612167
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
    Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE.
    Cardiovasc Diabetol; 2021 Sep 04; 20(1):178. PubMed ID: 34481498
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.
    Ning G, Bandgar T, Hehnke U, Lee J, Chan JCN.
    Adv Ther; 2017 Sep 04; 34(9):2150-2162. PubMed ID: 28819835
    [Abstract] [Full Text] [Related]

  • 38. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
    Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.
    Lancet; 2013 Oct 26; 382(9902):1413-23. PubMed ID: 23948125
    [Abstract] [Full Text] [Related]

  • 39. Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus.
    Tschöpe D, Bramlage P, Schneider S, Gitt AK.
    Diab Vasc Dis Res; 2016 Jan 26; 13(1):2-12. PubMed ID: 26567123
    [Abstract] [Full Text] [Related]

  • 40. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
    Pérez-Belmonte LM, Osuna-Sánchez J, Millán-Gómez M, López-Carmona MD, Gómez-Doblas JJ, Cobos-Palacios L, Sanz-Cánovas J, Barbancho MA, Lara JP, Jiménez-Navarro M, Bernal-López MR, Gómez-Huelgas R.
    Ann Med; 2019 Jan 26; 51(3-4):252-261. PubMed ID: 31037970
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.